Foghorn Therapeutics Inc. (FHTX) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $5.82, but acceptable to hold if already in. Reason: Market cap $356M below $400M minimum.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic... Read more
Hold if already holding. Not a fresh buy at $5.82, but acceptable to hold if already in. Reason: Market cap $356M below $400M minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $356M below $400M minimum. Not in investable universe. Score 6.0/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 65d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About Foghorn Therapeutics Inc.
About Foghorn Therapeutics Inc.
Foghorn Therapeutics is advancing more than seven chromatin-regulatory-system programs, with just one, FHD-909 — a SMARCA2 inhibitor Lilly selected for clinical development in February 2024 — in Phase 1 testing after dosing its first patient in October 2024. The company employed 106 people as of December 31, 2025, has no product revenue, and carries a $632.5 million accumulated deficit funded primarily through its Lilly collaboration, prior stock offerings, and its IPO.
Foghorn generates no product sales; its economics run through collaboration payments and equity investment from Eli Lilly, which entered a strategic collaboration in December 2021 covering a U.S. co-development and co-commercialization agreement for the SMARCA2 oncology program (FHD-909) plus an undisclosed second oncology target and three additional discovery programs. The company's Gene Traffic Control platform screens for enzyme inhibitors, protein degraders, and transcription-factor disruptors against named targets including SMARCA2, CBP, EP300, and ARID1B, and Foghorn has disclosed plans to file up to four Investigational New Drug applications over the next two years, spanning oncology and, longer term, other disease areas such as immunology. Early manufacturing of clinical supplies runs through third-party arrangements rather than in-house production, consistent with a discovery-stage biotech that has not yet built commercial infrastructure.
Show full overview
FHD-909 functions as Foghorn's sole clinical-stage bet: every other program in the pipeline remains preclinical, and the filing states plainly that the company has one product candidate, FHD-909, partnered with Lilly, in Phase 1 development. Because Lilly leads and funds that trial under the 2021 collaboration agreement, Foghorn's near-term catalysts depend on a partner's execution and prioritization rather than its own clinical operations — a structure that also means the roughly $632.5 million the company has spent to date has not yet produced a single late-stage or commercial asset it fully controls.
From Foghorn Therapeutics Inc.'s most recent 10-K filing, extracted August 30, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $5.82, but acceptable to hold if already in. Reason: Market cap $356M below $400M minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $356M below $400M minimum. Not in investable universe. Target $9.96 (+71.1%), stop $5.42 (−7.4%), A.R:R 4.7:1. Score 6.0/10, moderate confidence.
Take-profit target: $9.96 (+70.9% upside). Target $9.96 (+71.1%), stop $5.42 (−7.4%), A.R:R 4.7:1. Stop-loss: $5.42.
Market cap $356M below $400M minimum.
Foghorn Therapeutics Inc. trades at a P/E of N/A (forward -5.5). TrendMatrix value score: 6.9/10. Verdict: Hold.
16 analysts cover FHTX with a consensus score of 4.4/5. Average price target: $11.
What does Foghorn Therapeutics Inc. do?Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of...
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.